Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,818
datasets available to search
ShareScore release 0.7.1
Dataset results
6,818 results for “inhibition”
Fig. 3 in Nerolidol inhibits proliferation of leiomyoma cells via reactive oxygen species-induced DNA damage and downregulation of the ATM/ Akt pathway
Fig. 3. Nerolidol treatment led to the generation of intracellular ROS and impaired the mitochondrial membrane potential. (A) ELT3 cells were harvested after trypsin/EDTA treatment and then treated with 20 mM NAC, followed by DCFDA staining for 30 min. The cells were then treated with nerolidol for another additional 30 min, and DCF fluorescence was detected using flow cytometry. H2O2 was used as the positive control. The data were analyzed using the FlowJo software. (B, C) ELT3 cells were harvested and treated with nerolidol for 30 min. The cells were then stained with JC-1 dye for 15 min, followed by flow cytometry analysis. FCCP was used as the positive control. The data were analyzed using the FlowJo software. (B) The gated cells in the graphs indicate the cells with low mitochondrial membrane potential, and the quantitative results are plotted in (C). (D) ELT3 cells were treated with the indicated concentration of nerolidol for 48 h with or without co-treatment with 5 mM NAC. Cell proliferation was determined using the MTT assay. Ethanol (1 %) was used as the vehicle control. The data are presented as relative percentage compared to that of the vehicle control. (E) ELT3 cells were treated with the indicated concentration of nerolidol for 48 h with or without co-treatment with 20 μM ferrostatin-1. Cell proliferation was determined using the MTT assay. Ethanol (1 %) was used as the vehicle control. The data are presented as relative percentage compared to that of the vehicle control. The p-values were calculated using one-way ANOVA with Tukey's multiple post hoc test for each group. *, p <0.05; ***, p <0.001 compared to the vehicle control group (C). ***, p <0.001 compared to the nerolidol single treatment group (D, E).
Fig. 4 in Nerolidol inhibits proliferation of leiomyoma cells via reactive oxygen species-induced DNA damage and downregulation of the ATM/ Akt pathway
Fig. 4. Treatment with nerolidol triggered DNA damage in rat leiomyoma cells. (A, B) ELT3 cells were harvested and treated with 100 μM nerolidol for 30 min, followed by determination of DNA damage using the comet assay. H2O2 (200 μM) was used as the positive control. The tail moments are indicated by red arrows in (A), as quantified using a live video imaging system, and dot plots show the mean ± SD in (B). (C, D, E) ELT3 cells were treated with 100 μM nerolidol for 1 h, followed by incubation with anti-p-γH2AXser139 antibody and FITC-conjugated secondary antibody. Nuclei were visualized using DAPI (blue). (C) P-γH2AXser139 expression was quantified using an automated imaging system. The relative positive cell number and the nuclear p-γH2AXser139 intensities are plotted in (D) and (E), respectively. The p-value was calculated using one-way ANOVA with Tukey's multiple post hoc test for each group. *, p <0.05; **, p <0.01, and ***, p <0.001 compared to the vehicle control group (1 % EtOH). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2. Nerolidol induced G1 in Nerolidol inhibits proliferation of leiomyoma cells via reactive oxygen species-induced DNA damage and downregulation of the ATM/ Akt pathway
Fig. 2. Nerolidol induced G1 cell cycle arrest by downregulating Akt phosphorylation and cell cycle-related proteins. ELT3 cells were treated with the indicated concentrations of nerolidol for 48 h and were then harvested after trypsin/EDTA treatment. (A, B) For cell cycle analysis, the harvested cells were fixed with 70 % ethanol, followed by propidium iodide staining, and the DNA content was measured using flow cytometry. The results were analyzed using the FlowJo software (A). Blue, olive green, and green represent the G1, S, and G2/M phases, respectively. The percentage of each cell cycle phase was plotted in (B). The p-value was calculated using one-way ANOVA with Tukey's multiple post hoc test for each group.*, p <0.05; **, p <0.01, and ***, p <0.001 compared to the vehicle control group (1 % EtOH). (C) Total cellular protein content was measured, and the expression levels of phosphorylated Akt, total Akt, cyclin D1, CDK4, and CDK6 were determined using western blot analysis. β-Actin was used as the loading control. The inserted numbers in (C) indicate the relative expression level compared to that of the vehicle control (indicated as 0 μM). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 1 in Nerolidol inhibits proliferation of leiomyoma cells via reactive oxygen species-induced DNA damage and downregulation of the ATM/ Akt pathway
Fig. 1. Nerolidol inhibited the proliferation of rat leiomyoma cells. ELT3 cells were seeded in 24-well plates and treated with the indicated concentrations of nerolidol for 48 h. (A) Images were captured under an inverted microscope at 100 × magnification. (B) The cells were trypsinized, and the number of viable (upper panel) or dead (lower panel) cells was counted after staining with trypan blue with a hemocytometer. (C) Cell proliferation was also determined using the MTT assay. Ethanol (1 %) was used as the vehicle control, which is indicated as 0 μM. The data are presented as relative percentage compared to the vehicle control. The p-value was calculated using one way ANOVA with Tukey's multiple post hoc test for each group. *, p <0.05 and ***, p <0.001 compared to the vehicle control group. The IC50 values were calculated using the IC50 Calculator (https://www.aatbio.com/tools/ic50-calculator).
Fig. 5 in Diverse alkaloids from the aerial parts of Aconitum carmichaelii and antiproliferative activity of costemline via inhibiting SIRT1/ROCK1/ P-STAT3 pathways
Fig. 5. The protein levels of ROCK1/SIRT1 and STAT3/P-STAT3 in colorectal cancer (CRC). (A) Western blot was used to analyze the expression or phosphorylation level of ROCK1, SIRT1 and STAT3 after HCT116 cells in the above groups were treated with 20 μM/40 μM compound 1 for 24 h. (B) At the protein level, the relative expression of SIRT1 and ROCK1/STAT3 signal was inhibited by compound 1 in HCT-116 cells. **p <0.01, ***p <0.001, ****p <0.0001 vs. control group.
Fig. 4. Compound 1 in Diverse alkaloids from the aerial parts of Aconitum carmichaelii and antiproliferative activity of costemline via inhibiting SIRT1/ROCK1/ P-STAT3 pathways
Fig. 4. Compound 1 inhibited invasion of HCT116 colon cancer cells in a transwell assay, which showed by representative images (A) and attached data (B). Cells were incubated with compound 1 (a) 0 μM, (b) 5 μM, (c) 10 μM for 24 h (original magnification, × 200). Quantitative data are presented as the mean ± standard deviation of 3 replicates, relative to the 0 μM control group. **p <0.01 vs. the 0 μM control group.
Fig. 4 in Essential structural features of (2Z,4E)-5-phenylpenta-2,4-dienoic acid for inhibition of root gravitropism
Fig. 4. Inhibition tests of gravitropic bending at various concentrations of ku- 76 ((a) control, (b) [ku-76]; A: 10 μM, B: 5 μM, C: 1 μM), (c) Effect of ku-76 on gravitropism, (d) elongation. Data represent mean ± SD. Asterisk indicates statistically significant differences between treatments and control at p <0.05 (Welch t-test, n = 7).
Fig. 7 in Essential structural features of (2Z,4E)-5-phenylpenta-2,4-dienoic acid for inhibition of root gravitropism
Fig. 7. Inhibitory activity tests of gravitropic bending and elongation for skeletal analogues (50 μM except for ku-76 (10 μM). Data for (A) gravitropic bending and (B) elongation represent mean ± SD. Asterisk indicates statistically significant differences between treatments and control at p <0.05 (Welch t-test, n = 7).
Fig. 3 in Essential structural features of (2Z,4E)-5-phenylpenta-2,4-dienoic acid for inhibition of root gravitropism
Fig. 3. Evaluation method for inhibitory activity against root gravitropic bending. Gravity vectors before (g1) and after (g2) reorientation are indicated. The length (l, cm) of the root length and the angle (θ, degree) of the curvature after reorientation were measured. The figure represents the lettuce seeding (mock treated).
Fig. 8 in Essential structural features of (2Z,4E)-5-phenylpenta-2,4-dienoic acid for inhibition of root gravitropism
Fig. 8. Inhibitory activity tests for amide, alcohol, ester analogues (50 μM). Data of (A) gravitropic bending and (B) elongation represent mean ± SD. Asterisk indicates statistically significant differences between treatments and control at p <0.05 (Welch t-test, n = 7).
Fig. 6. ABDCM dose-dependently inhibited TMEM16A in Isolation of CFTR and TMEM16A inhibitors from Neorautanenia mitis (A. Rich) Verdcourt: Potential lead compounds for treatment of secretory diarrhea
Fig. 6. ABDCM dose-dependently inhibited TMEM16A in Calu-3 cells. (A) Representative trace of change in Cl current. ABDCM at indicated concentration were applied 20 min prior to TMEM16A activation by Eact (10 μM). (B) Dose-response relationship of TMEM16A inhibition by ABDCM. Data were fitted to the Hill equation and expressed as means of Eact-induced Cl current (mean ± S.E.M, n = 3).
Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition
<p>Data-Sets of, “Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition”</p> <p>The Dataset (Derived from <a href="https://doi.org/10.1111/bph.16251">https://doi.org/10.1111/bph.16251</a>) contains the original figures and tables as PNG-format (10.1111_bph.16251_Figure 1-4.PNG; 10.1111_bph.16251_Table1-2.PNG and supplemental information 10.1111_bph.16251_FigS1-S2.PNG; 10.1111_bph.16251_TableS1-S6.PNG), as well as the graphical abstract.PNG</p> <p>Corresponding raw data and subsequent data analysis obtained from LC-MS/MS analysis and reused data on THF, THE and allo-THE and clinical parameters as well as the statistical evaluation of obtained data are provided as raw-files and corresponding meta data-files (FAIR-Principle).</p> <p>Fig 2:</p> <p>Two files in CSV format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_3.csv and 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_28_1.csv). Detailed description of the LC-MS/MS method is provided as pdf-Format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_M_2.pdf). All further experiment related information provided as one meta-data-file (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_3_M .txt) in txt format and two files containing further related information (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_M_A1-2 .pdf) PDF format.</p> <p>Fig3:</p> <p>Two files in CSV format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_4.csv; 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_28_2.csv). One meta data file as pdf-format with detailed LC-MS/MS method description 310030-(214978_10.1111_bph.16251_CGC_Human_Biomarker_4_M_2.pdf). All further related information are provided as one meta-data-file (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_4_M .txt) in txt format. Cohort B related information is provided as three files in pdf- format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_M_B1-3).</p> <p>Fig 4:</p> <p>Six files in CSV format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_3-5 .csv, 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_26_1.csv and 214978_10.1111_bph.16251_CGC_Human_Biomarker_28_1-2.csv). Two meta data file as pdf-format with detailed LC-MS/MS method descriptions (214978_10.1111_bph.16251_CGC_Human_Biomarker_4_M_2-3 .pdf ). All further related information are provided as one meta-data-file (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_4_3-5_M.txt) in txt format. Cohort related information is provided as five files in pdf- format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_M_A1-2 and B1-3.pdf) Statistical analysis is provided as R-File (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_26_M_1_1.R).</p> <p>Tab1:</p> <p>One file in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_1 .csv). One meta file as pdf-format with detailed LC-MS/MS method description (214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_1.pdf ). All further related information are provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_1_M.txt) in txt format. Cohort A related information is provided as two files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_A1-2).</p> <p>Tab2:</p> <p>One file in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_2.csv). One meta data file as pdf-format with detailed LC-MS/MS method description (214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_1.pdf ). All further related information are provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_2_M.txt) in txt format. Cohort B related information is provided as three files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_B1-3).</p> <p>Fig S1:</p> <p>Four files in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_3-4.csv and 214978_10.1111_BPH.16251_CGC_Human_Biomarker_28_1-2.csv). One meta data file as pdf-format with detailed LC-MS/MS method description (214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_2.pdf ). All further related information are provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_3-4_M.txt) in txt format. Cohort A and B related information is provided as five files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_A1-2 and-B1-3).</p> <p>Fig S2:</p> <p>Five files in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_3-4.csv and 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_26_2.csv, 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_28_1-2.csv) and one file as R-File (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_26_2_M1.R). One meta data file as pdf-format provides detailed LC-MS/MS method description (214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_2.pdf). All further related information are provided as one meta-data-file (310030 214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_26_2_M.txt) in txt format. Cohort A and B related information is provided as five files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_A1-2 and-B1-3).</p> <p>Tab S1:</p> <p>One file in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_28_3.csv). All further related information are provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_28_3_M.txt) in txt format. Cohort A related information is provided as two files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_A1-2). </p> <p>TabS2:</p> <p>One file in CSV format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_28_4.csv). All further related information are provided as one meta-data-file (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_28_4_M.txt) in txt format. Cohort B related information is provided as three files in pdf- format (310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_M_B1-3).</p> <p>TabS3:</p> <p>One file in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_3.csv). Detailed description of the LC-MS/MS method is provided as pdf-Formate (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_2.pdf) All further experiment related information provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_26_3_M.txt) in txt format and two files containing further related information (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_A1-2 .pdf) PDF format.</p> <p>Tab S4:</p> <p>Three file in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_5.csv, 310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_26_1-2.csv). Detailed description of the LC-MS/MS methods is provided two files pdf-Format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_2-3.pdf) All further experiment related information provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_26_4_M.txt) in txt format. Cohort related information is provided as two files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_A1-2. Statistical analysis is provided as R-File (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_26_M_1.R).</p> <p>TabS5:</p> <p>One files in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_4.csv One meta data file as pdf-format with detailed LC-MS/MS method description (214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_2.pdf ). All further related information are provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_26_5_M.txt) in txt format. Cohort B related information is provided as three files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_B1-3).</p> <p>TabS6:</p> <p>Four files in CSV format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_4-5.csv 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_28_4.csv; 310030-214978_10.1111_bph.16251_CGC_Human_Biomarker_26_1.csv). One meta data file as pdf-format with detailed LC-MS/MS method description (214978_10.1111_BPH.16251_CGC_Human_Biomarker_4_M_2-3.pdf ). All further related information are provided as one meta-data-file (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_26_6_M.txt) in txt format. Cohort B related information is provided as three files in pdf- format (310030-214978_10.1111_BPH.16251_CGC_Human_Biomarker_M_B1-3).</p>
Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy
ClinicalTrials.gov study NCT00367562. IPD Sharing: Not stated. Countries: 1. Publications: 10.
Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System
ClinicalTrials.gov study NCT02010905. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa
ClinicalTrials.gov study NCT03001622. IPD Sharing: NO. Countries: 1. Publications: 1.
Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)
ClinicalTrials.gov study NCT04790240. IPD Sharing: YES. Countries: 1. Publications: 8.
Pain Inhibition and Facilitation in Recurrent Low Back Pain
ClinicalTrials.gov study NCT03463759. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes
ClinicalTrials.gov study NCT02319941. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
ClinicalTrials.gov study NCT05638763. IPD Sharing: NO. Countries: 1. Publications: 3.
Study of Cognitive Inhibition Disorders in Depressed Older Suicide Attempters
ClinicalTrials.gov study NCT01333215. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.